New combo therapy aims to shrink lung tumors before surgery
NCT ID NCT04933903
Summary
This study is testing a new pre-surgery treatment for people with operable non-small cell lung cancer. Before having surgery to remove the tumor, participants receive a combination of two immunotherapy drugs (ipilimumab and nivolumab) along with a short, targeted course of low-dose radiation. The main goal is to see if this combination can significantly shrink or eliminate the cancer in the removed tissue, which may improve long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rhode Island Hospital
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.